Stem Cells and Antibodies in Drug Discovery Europe 2018

Home
|
Posters
|

Keynote Speakers

Matthew Daniels Wellcome Trust Intermediate Clinical Fellow, Honorary Consultant Cardiologist, University of Oxford	Stefan Dubel Full Professor and Director, Technische Universität Braunschweig	Paul French Professor, Department of Physics and Photonics Group, Imperial College London	Gary Gintant Senior Research Fellow, Abbvie	David Hay Chair of Tissue Engineering, MRC Centre for Regenerative Medicine, University of Edinburgh	Stephen Helliwell Senior Investigator, Novartis Institutes for BioMedical Research
Robert Williams Chief Drug Development Scientist, Cancer Research UK

Overview

Stem Cells and Antibodies in Drug Discovery 2018 and Antibodies in Drug Discovery 2018 and High-Content & Phenotypic Screening 2018 -- Explore the emerging trends and technologies impacting Drug Discovery, circa 2018.

Stem Cells in Drug Discovery 2018: Hear from and network with researchers who are currently screening for efficacy and toxicity using iPS cell lines, and those responsible for developing the techniques and technologies. There will also be discussions on industry and regulatory developments that are shaping the future of stem cell usage in drug discovery.

Antibodies in Drug Discovery 2018: The focus is to explore the latest developments in the design and engineering of antibodies in relation to the burgeoning field of biotherapeutics. Topics to be addressed include, engineering challenges and techniques, new technologies and business hurdles when developing antibodies, the latest developments in autoimmune and infectious disease research. If you work in antibody drug discovery research you will benefit from the expert knowledge of academic and industry leaders, whilst networking with the technology providers.

Information and Local Registration Facilities for this Conference are also available in:

Japanese |

Korean |

Chinese (Simplified) |

Chinese (Traditional)

Agenda Topics

3D-Cell Based Models
Antibodies for New Targets
Antibody Drug Conjugates (ADCs)
Antibody Screening
Humanized Single Domain Antibodies for Research and Therapeutic Applications
iPSC-derived Cells for Toxicity Testing & Screening
Monoclonal Antibodies
Scale Up and Quality Control
Screening Technologies, Instrumentation and Reagents
Stem Cells in Drug Discovery and Toxicity Screening
Targeting Ion Channels with Biologics

Sponsorship and Exhibition Opportunities

Exhibition Team,
exhibitors@selectbio.com
+44 (0) 1206 501654

Distinguished Faculty

Nicholas Hannan, Assistant Professor, University of Nottingham
Masatoshi Suzuki, Associate Professor, Department of Comparative Biosciences and Stem Cell & Regenerative Medicine Center, University of Wisconsin-Madison
Alice Pébay, Associate Professor, Principal Research Fellow, University of Melbourne & Centre for Eye Research Australia
Sanjay Sinha, BHF Senior Research Fellow, University of Cambridge
Davide Danovi, Director, Cell Phenotyping Platform, Kings College London
Peter O'Brien, Head of Clinical Pathology, University College Dublin
Jacqueline Chuah, Lab Officer, Institute of Bioengineering and Nanotechnology, A*Star
E. Sally Ward, Professor, Texas A&M University Health Science Center
Hugh Byrne, Professor, Dublin Institute of Technology
Wing Chang, R&D Director, STEMCELL Technologies
Win-Yan Chan, Research Scientist, UCB
Simon Hufton, Section Head Molecular Immunology, National Institute for Biological Standard and Control (NIBSC)
Hua Rong Lu, Senior Principal Scientist, Discovery Sciences, Janssen Pharmaceutical NV
Tristan Vaughan, Vice President, R&D, Antibody Discovery and Protein Engineering, MedImmune Ltd

Corporate Sponsors	Web Sponsors	Offical Journal Partner	Networking